Physiologically based pharmacokinetic (PBPK) modeling for prediction of celecoxib pharmacokinetics according to CYP2C9 genetic polymorphism

• Published in: Archives of pharmacal research Vol. 44; no. 7; pp. 713 - 724
• Main Authors: Kim, Young-Hoon, Kang, Pureum, Cho, Chang‑Keun, Jung, Eui Hyun, Park, Hye-Jeong, Lee, Yun Jeong, Bae, Jung‑Woo, Jang, Choon-Gon, Lee, Seok-Yong
• Format: Journal Article
• Language: English
• Published: Seoul Pharmaceutical Society of Korea 01.07.2021; 대한약학회
• Subjects: Administration, Oral; Celecoxib - administration & dosage; Celecoxib - adverse effects; Celecoxib - pharmacokinetics; Cyclooxygenase 2 Inhibitors - administration & dosage; Cyclooxygenase 2 Inhibitors - adverse effects; Cyclooxygenase 2 Inhibitors - pharmacokinetics; Cytochrome P-450 CYP2C9 - genetics; Cytochrome P-450 CYP2C9 - metabolism; Drug-Related Side Effects and Adverse Reactions - genetics; Drug-Related Side Effects and Adverse Reactions - prevention & control; genetic polymorphism; genomics; genotype; Healthy Volunteers; Humans; Medicine; model validation; Models, Biological; nonsteroidal anti-inflammatory agents; oral administration; osteoarthritis; pain; Pharmacogenomic Variants; pharmacokinetics; Pharmacology/Toxicology; Pharmacy; precision medicine; Precision Medicine - methods; prediction; prostaglandin synthase; Research Article; rheumatoid arthritis; 약학; Dose optimization; PBPK; CYP2C9; Genotype; Celecoxib; Precision medicine
• ISSN: 0253-6269; 1976-3786; 1976-3786
• DOI: 10.1007/s12272-021-01346-2

Celecoxib is a non-steroidal anti-inflammatory drug (NSAID) and a representative selective cyclooxygenase (COX)-2 inhibitor, which is commonly prescribed for osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute pain, and primary dysmenorrhea. It is mainly metabolized by CYP2C9 and partly by CYP3A4 after oral administration. Many studies reported that CYP2C9 genetic polymorphism has significant effects on the pharmacokinetics of celecoxib and the occurrence of adverse drug reactions. The aim of this study was to develop a physiologically based pharmacokinetic (PBPK) model of celecoxib according to CYP2C9 genetic polymorphism for personalized pharmacotherapy. Initially, a clinical pharmacokinetic study was conducted where a single dose (200 mg) of celecoxib was administered to 39 healthy Korean subjects with CYP2C9*1/*1 or CYP2C9*1/*3 genotypes to obtain data for PBPK development. Based on the conducted pharmacokinetic study and a previous pharmacokinetic study involving subjects with CYP2C9*1/*13 and CYP2C9*3/*3 genotype, PBPK model for celecoxib was developed. A PBPK model for CYP2C9*1/*1 genotype group was developed and then scaled to other genotype groups ( CYP2C9*1/*3 , CYP2C9*1/*13 and CYP2C9*3/*3 ). After model development, model validation was performed with comparison of five pharmacokinetic studies. As a result, the developed PBPK model of celecoxib successfully described the pharmacokinetics of each CYP2C9 genotype group and its predicted values were within the acceptance criterion. Additionally, all the predicted values were within two-fold error range in comparison to the previous pharmacokinetic studies. This study demonstrates the possibility of determining the appropriate dosage of celecoxib for each individual through the PBPK modeling with CYP2C9 genomic information. This approach could contribute to the reduction of adverse drug reactions of celecoxib and enable precision medicine.